ONO Pharmaceutical acquires Deciphera Pharmaceuticals for $2.4bn in cash to expand oncology presence and global specialty pharma goals.

ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4bn in cash, merging them with a subsidiary to enhance its oncology presence and global specialty pharma goals. The deal adds Deciphera's kinase drug research, US/EU commercial platforms, and global clinical development capabilities to ONO. JPMorgan, Goodwin Procter, BofA Securities, and Greenberg Traurig serve as advisors for the respective companies.

April 29, 2024
5 Articles